All In Biotech

Drug Trial Radar · NCT05512806

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

A Randomized, 6-period, 6-treatment, Single-Dose, Crossover Study to Assess the Pharmacokinetics of AZD5462 Film-coated Tablet Formulation, to Assess the Relative Bioavailability of AZD5462 Film-coated Tablet Formulation vs Oral Solution, and to Assess the Influence of Food on the Pharmacokinetics of AZD5462 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Aug 24, 2022

Primary completion

Nov 7, 2022

Study completion Nov 7, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Aug 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the pharmacokinetics of AZD5462 film-coated tablet formulation in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • AZD5462Drug

    Participants will receive AZD5462 orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under plasma concentration time curve from zero to infinity (AUCinf)Time frame: Day 1 to Day 17
  2. Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)Time frame: Day 1 to Day 17
  3. Maximum observed plasma (peak) drug concentration [Cmax]Time frame: Day 1 to Day 17
  4. Area under plasma concentration time curve from zero to infinity (AUCinf)Time frame: Day 1 to Day 17
  5. Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)Time frame: Day 1 to Day 17
  6. Maximum observed plasma (peak) drug concentration [Cmax]Time frame: Day 1 to Day 17
  7. Area under plasma concentration time curve from zero to infinity (AUCinf)Time frame: Day 1 to Day 17
  8. Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)Time frame: Day 1 to Day 17
  9. Maximum observed plasma (peak) drug concentration [Cmax]Time frame: Day 1 to Day 17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Brooklyn, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.